3月21日,阿斯利康今年迄今在中国最大的动作官宣了。阿斯利康宣布了一项25亿美元的投资计划,在北京建立第六个全球战略研发中心,聚焦于肿瘤、心血管疾病、呼吸系统疾病、免疫学以及人工智能应用等前沿领域的研究和开发,并达成多项重大研发与生产合作,其中包括将与康泰生物成立合资公司,在呼吸等疾病领域开展创新疫苗的开发、生产和商业化。图丨北京全球战略研发中心01从分子构想到临床破局,推动科学与创新此次在北京...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.